ClinicalTrials.gg
CompletedNCT01631552Updated Aug 12, 2021Results posted

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

A Phase 1/2 interventional study of Sacituzumab Govitecan-hziy (SG) in Gastric Adenocarcinoma, Esophageal Cancer and Hepatocellular Carcinoma, sponsored by Gilead Sciences. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-12.

Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
515
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 676 studies in Esophageal Neoplasms with a site in United States — 122 open to participants now, 172 under way, 2 of them phase 3. Esophageal Neoplasms · United States.

Enrollment
26th of 525
515 · median 42
Started
2012
with 18 others
Phase 1/2
67 of 676
16 open now
Registered
312th of 676
by date

Among the 676 studies in Esophageal Neoplasms with a site in United States, this one is the 26th largest by enrollment of the 525 interventional ones that give a count, is one of 19 that started in 2012, is one of 67 in phase 1/2, and was the 312th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

122 of the 676 studies in Esophageal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 676 studies in Esophageal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of sacituzumab govitecan-hziy administered in 21-day treatment cycles at a dose selected in Phase I.

Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

Read the detailed description

The outcome measures are planned to be assessed up to the data cutoff date. Following the data cutoff date, the participants will either stay on the study and will be followed for safety data collection or rolled into another Gilead-sponsored study. Therefore, only safety data will be collected after the data cutoff date.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Esophageal Cancer
  • Hepatocellular Carcinoma
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Ovarian Epithelial Cancer
  • Carcinoma Breast Stage IV
  • Hormone-refractory Prostate Cancer
  • Head and Neck Cancers- Squamous Cell
  • Renal Cell Cancer
  • Urinary Bladder Neoplasms
  • Cervical Cancer
  • Endometrial Cancer
  • Glioblastoma Multiforme
  • Triple Negative Breast Cancer
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals able to understand and give written .
  • or cytologically confirmed epithelial cancer of one of the following types:

    • Gastric adenocarcinoma (GC)
    • Esophageal cancer (EC)
    • Hepatocellular carcinoma (HCC)
    • Non-small-cell lung cancer (NSCLC)
    • Small-cell lung cancer (SCLC)
    • Epithelial ovarian cancer (EOC)
    • Cervical Cancer
    • Endometrial Cancer
    • Triple-negative breast cancer (TNBC)
    • Non-triple-negative breast cancer
    • Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and anaplastic thyroid cancer)
    • Glioblastoma multiforme (GBM)
    • Hormone- prostate cancer (HRPC)
    • Head and neck cancers- squamous cell (SCCHN)
    • Renal cell cancer (clear cell) (RCC)
    • Urothelial cancer
    • Stage IV () disease (except for individuals with GBM).
  • Refractory to or relapsed after at least one prior standard therapeutic regimen
  • Adequate performance status ( 0 or 1)
  • Expected survival ≥ 6 months.
  • by CT or MRI.
  • At least 2 weeks beyond treatment (chemotherapy, drugs including small molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities to Grade 1 or less (except alopecia).
  • At least 2 weeks beyond high dose systemic (however, low dose corticosteroids \< 20 mg prednisone or equivalent daily are permitted).
  • Adequate hematology without ongoing transfusional support ( > 9 g/dL, (ANC) > 1,500 per mm\^3, > 100,000 per mm\^3).
  • Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional (IULN), ≤ 1.5 IULN, (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).
  • Otherwise, all toxicity at study entry ≤ Grade 1.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Women of and fertile men unwilling to use effective during study until conclusion of 12-week post-treatment evaluation period.
  • Individuals with Gilbert's disease.
  • Individuals with can be enrolled only if treated, non-progressive brain metastases and off high-dose (> 20 mg prednisone or equivalent) for at least 4 weeks.
  • Presence of bulky disease (defined as any single mass > 7 cm in its greatest dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be considered for enrollment after discussion and approval with the medical monitor.
  • Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.
  • Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior must have had at least a 3-year disease-free interval.
  • Individuals known to be positive, positive, or positive.
  • Known history of unstable angina, MI, or CHF present within 6 months or cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.
  • Known history of clinically significant active , or other moderate-to-severe chronic respiratory illness present within 6 months.
  • Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.
  • Infection requiring intravenous antibiotic use within 1 week.
  • History of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior irinotecan,
  • Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy (SG) 8 mg/kg

    Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.

    Drug: Sacituzumab Govitecan-hziy (SG)

  • Experimental
    SG 10 mg/kg

    Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.

    Drug: Sacituzumab Govitecan-hziy (SG)

  • Experimental
    SG 12 mg/kg

    Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.

    Drug: Sacituzumab Govitecan-hziy (SG)

  • Experimental
    SG 18 mg/kg

    Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.

    Drug: Sacituzumab Govitecan-hziy (SG)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population.

    Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months) plus 30 days

  2. Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death

    Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).

    Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)

  3. Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events

    Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).

    Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)

  4. Objective Response Rate (ORR) by Independent Central Review (ICR)

    ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by ICR assessment according to RECIST1.1. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \<10 mm. PR was defined as ≥ 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  5. Objective Response Rate by Local Assessment

    ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by local assessment. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \<10 mm. PR was defined as ≥3 0% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by Local Assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

Secondary outcomes

  1. Duration of Response by ICR

    Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  2. Duration of Response by Local Assessment

    Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, duration of response by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  3. Time to Response by ICR

    Time to response was defined as the time from the first dose to the first documentation of response (PR or CR). Per planned analysis, time to response by ICR was assessed for the TNBC Target Population only.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  4. Time to Response by Local Assessments

    Time to response was defined as the time from the first dose to the first documentation of response (PR or CR). Per planned analysis, time to response by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  5. Clinical Benefit Rate (CBR) by Local Assessment

    Clinical benefit rate (CR+PR+\[stable disease (SD) ≥ 6 months\]) is defined as those participants with best response as CR or PR or else SD with a duration of at least 6 months. SD for 6 months duration was defined as the time from the first dose to the first documentation of PD or to the last adequate response assessment prior to data cut-off date, whichever is earlier. Per planned analysis, CBR by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  6. Progression Free Survival (PFS) by Local Assessment

    Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first. Per planned analysis, PFS by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  7. Overall Survival by Local Assessment

    Overall survival was defined as the time from the date of the first dose start date to the date of death due to any cause. Per planned analysis, overall survival by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

    Time frame: Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)

  8. Pharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

    T1/2 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. T1/2 is defined as apparent terminal elimination half-life (h); calculated as 0.693/λz. The dose level evaluated for PK analysis was 10 mg/kg.

    Time frame: Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hours (± 30 minutes) for subsequent infusions

  9. PK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

    AUC0-24 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-24 is defined as area under the serum concentration-time curve from time 0 to 24 hours. The dose level evaluated for PK analysis was 10 mg/kg.

    Time frame: Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions

  10. PK Parameter: AUC0-168 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

    AUC0-168 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-168 is defined as area under the serum concentration-time curve from time 0 to 168 hours. The dose level evaluated for PK analysis was 10 mg/kg.

    Time frame: Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions

  11. PK Parameter: AUC0-inf of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

    AUC0-inf was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-inf is defined as area under the serum concentration-time curve from time 0 extrapolated to infinity. The dose level evaluated for PK analysis was 10 mg/kg.

    Time frame: Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions

  12. PK Parameter: Cmax of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

    Cmax was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. Cmax is defined as maximum observed serum concentration obtained directly from the observed concentration-time data. The dose level evaluated for PK analysis was 10 mg/kg.

    Time frame: Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions

07

Results

Posted Apr 6, 2021

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 17 December 2012. The last study visit occurred on 13 August 2020. Outcome Measures were assessed up to the data cutoff date of 01 March 2019. Following the data cutoff date, the participants either stayed on the study and were followed for safety data collection or rolled into another Gilead-sponsored study. Therefore, only safety data was collected after the data cutoff date.

Participant flow — Overall Study
MilestoneSacituzumab Govitecan-hziy (SG) 8 mg/kgSG 10 mg/kgSG 12 mg/kgSG 18 mg/kg
Started8342093
Enrolled and treated8140293
Completed8140093
Not completed22000

Outcome measures

PrimaryPercentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population.

Time frame:
First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months) plus 30 days
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events
Percentage of participantsTNBC Target PopulationHR+/HER2- mBC PopulationmUC PopulationOverall Safety Population (OSP)
Adverse Events100.0100.0100.099.8
Serious Adverse Events30.635.242.238.8
PrimaryPercentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death

Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).

Time frame:
First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death
Percentage of participantsTNBC Target PopulationHR+/HER2- mBC PopulationmUC PopulationOverall Safety Population (OSP)
Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death2.85.615.68.1
PrimaryPercentage of Participants Who Required Dose Interruption Due to Any Adverse Events

Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).

Time frame:
First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events
Percentage of participantsTNBC Target PopulationHR+/HER2- mBC PopulationmUC PopulationOverall Safety Population (OSP)
Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events45.446.351.151.7
PrimaryObjective Response Rate (ORR) by Independent Central Review (ICR)

ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by ICR assessment according to RECIST1.1. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \<10 mm. PR was defined as ≥ 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) by Independent Central Review (ICR)
Percentage of participantsTNBC Target Population
Objective Response Rate (ORR) by Independent Central Review (ICR)34.3 (25.4 to 44.0)
PrimaryObjective Response Rate by Local Assessment

ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by local assessment. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \<10 mm. PR was defined as ≥3 0% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by Local Assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Number · Percentage of participants
Objective Response Rate by Local Assessment
Percentage of participantsTNBC Target PopulationHR+/HER2- mBC PopulationmUC Population
Objective Response Rate by Local Assessment33.3 (24.6 to 43.1)31.5 (19.5 to 45.6)28.9 (16.4 to 44.3)
SecondaryDuration of Response by ICR

Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Duration of Response by ICR
monthsTNBC Target Population
Duration of Response by ICR9.1 (4.6 to 11.3)
SecondaryDuration of Response by Local Assessment

Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, duration of response by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Duration of Response by Local Assessment
monthsTNBC Target PopulationHR+/HER2- mBC PopulationmUC Population
Duration of Response by Local Assessment7.7 (4.9 to 10.8)8.7 (3.7 to 12.7)12.9 (3.8 to 22.5)
SecondaryTime to Response by ICR

Time to response was defined as the time from the first dose to the first documentation of response (PR or CR). Per planned analysis, time to response by ICR was assessed for the TNBC Target Population only.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Time to Response by ICR
monthsTNBC Target Population
Time to Response by ICR2.2 (1.6 to 7.6)
SecondaryTime to Response by Local Assessments

Time to response was defined as the time from the first dose to the first documentation of response (PR or CR). Per planned analysis, time to response by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Time to Response by Local Assessments
monthsTNBC Target Population (TNBC Population)HR+/HER2- mBC Population (Non-TNBC)mUC Population
Time to Response by Local Assessments2.0 (1.6 to 13.5)2.1 (1.4 to 7.8)1.9 (1.7 to 7.4)
SecondaryClinical Benefit Rate (CBR) by Local Assessment

Clinical benefit rate (CR+PR+\[stable disease (SD) ≥ 6 months\]) is defined as those participants with best response as CR or PR or else SD with a duration of at least 6 months. SD for 6 months duration was defined as the time from the first dose to the first documentation of PD or to the last adequate response assessment prior to data cut-off date, whichever is earlier. Per planned analysis, CBR by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) by Local Assessment
Percentage of participantsTNBC Target PopulationHR+/HER2- mBC PopulationmUC Population
Clinical Benefit Rate (CBR) by Local Assessment45.4 (35.8 to 55.2)44.4 (30.9 to 58.6)44.4 (29.6 to 60.0)
SecondaryProgression Free Survival (PFS) by Local Assessment

Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first. Per planned analysis, PFS by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Progression Free Survival (PFS) by Local Assessment
monthsTNBC Target PopulationHR+/HER2- mBC PopulationmUC Population
Progression Free Survival (PFS) by Local Assessment5.6 (4.8 to 6.6)5.5 (3.6 to 7.6)6.8 (3.6 to 9.7)
SecondaryOverall Survival by Local Assessment

Overall survival was defined as the time from the date of the first dose start date to the date of death due to any cause. Per planned analysis, overall survival by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.

Time frame:
Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)
Reported as:
Median · months
Overall Survival by Local Assessment
monthsTNBC Target PopulationHR+/HER2- mBC PopulationmUC Population
Overall Survival by Local Assessment13.0 (11.2 to 14.0)12.0 (9.0 to 18.2)16.8 (9.0 to 21.9)
SecondaryPharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

T1/2 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. T1/2 is defined as apparent terminal elimination half-life (h); calculated as 0.693/λz. The dose level evaluated for PK analysis was 10 mg/kg.

Time frame:
Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hours (± 30 minutes) for subsequent infusions
Reported as:
Geometric mean · hours
Pharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38
hoursSG 10 mg/kg
Total Antibody66.6 ± 14.4
SN-38G21.4 ± 24.5
Total SN-3820.2 ± 26.6
Sacituzumab Govitecan-hziy (SG)15.0 ± 15.3
Free SN-3817.1 ± 18.6
SecondaryPK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

AUC0-24 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-24 is defined as area under the serum concentration-time curve from time 0 to 24 hours. The dose level evaluated for PK analysis was 10 mg/kg.

Time frame:
Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions
Reported as:
Geometric mean · microgram*hour per liter
PK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38
microgram*hour per literSG 10 mg/kg
Total Antibody4940 ± 30.1
SN-38G0.370 ± 45.6
Total SN-3865.5 ± 29.2
Sacituzumab Govitecan-hziy (SG)3290 ± 25.2
Free SN-381.67 ± 58.5
SecondaryPK Parameter: AUC0-168 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

AUC0-168 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-168 is defined as area under the serum concentration-time curve from time 0 to 168 hours. The dose level evaluated for PK analysis was 10 mg/kg.

Time frame:
Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions
Reported as:
Geometric mean · microgram*hour per liter
PK Parameter: AUC0-168 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38
microgram*hour per literSG 10 mg/kg
Total Antibody20800 ± 22.2
SN-38G0.842 ± 50.0
Total SN-38107 ± 25.4
Sacituzumab Govitecan-hziy (SG)5050 ± 24.4
Free SN-383.08 ± 56.6
SecondaryPK Parameter: AUC0-inf of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

AUC0-inf was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-inf is defined as area under the serum concentration-time curve from time 0 extrapolated to infinity. The dose level evaluated for PK analysis was 10 mg/kg.

Time frame:
Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions
Reported as:
Geometric mean · microgram*hour per liter
PK Parameter: AUC0-inf of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38
microgram*hour per literSG 10 mg/kg
Total Antibody25100 ± 20.5
SN-38G0.850 ± 50.7
Total SN-38107 ± 25.5
Sacituzumab Govitecan-hziy (SG)5050 ± 24.4
Free SN-383.08 ± 56.6
SecondaryPK Parameter: Cmax of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38

Cmax was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. Cmax is defined as maximum observed serum concentration obtained directly from the observed concentration-time data. The dose level evaluated for PK analysis was 10 mg/kg.

Time frame:
Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions
Reported as:
Geometric mean · microgram per liter
PK Parameter: Cmax of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38
microgram per literSG 10 mg/kg
Total Antibody245 ± 26.9
SN-38G0.0206 ± 50.4
Total SN-384.39 ± 25.2
Sacituzumab Govitecan-hziy (SG)220 ± 24.7
Free SN-380.0992 ± 61.1

Adverse events

Collected over - Adverse Events: First dose date up to 91.88 months plus 30 days - All-Cause Mortality: First dose date up to 91.88 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Safety Population422/495 (85.3%)192/495 (38.8%)490/495 (99%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventOverall Safety Population
Febrile neutropeniaBlood and lymphatic system disorders20/495
DiarrhoeaGastrointestinal disorders18/495
PneumoniaInfections and infestations14/495
DyspnoeaRespiratory, thoracic and mediastinal disorders12/495
VomitingGastrointestinal disorders11/495
NauseaGastrointestinal disorders10/495
NeutropeniaBlood and lymphatic system disorders7/495
Small intestinal obstructionGastrointestinal disorders7/495
Pleural effusionRespiratory, thoracic and mediastinal disorders7/495
Abdominal painGastrointestinal disorders6/495
Most frequent other events
Showing 10 of 60
Most frequent other events
EventOverall Safety Population
NauseaGastrointestinal disorders342/495
DiarrhoeaGastrointestinal disorders303/495
FatigueGeneral disorders280/495
VomitingGastrointestinal disorders220/495
AlopeciaSkin and subcutaneous tissue disorders216/495
AnaemiaBlood and lymphatic system disorders207/495
NeutropeniaBlood and lymphatic system disorders196/495
ConstipationGastrointestinal disorders184/495
Decreased appetiteMetabolism and nutrition disorders171/495
Abdominal painGastrointestinal disorders108/495

Baseline characteristics

Age, Continuous
Age, Continuous(years)SG 8mg/kgSG 10 mg/kgSG 12 mg/kgSG 18 mg/kgTotal
Mean61.1 ± 10.9159.8 ± 11.2859.1 ± 10.5356.0 ± 4.0060.0 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)SG 8mg/kgSG 10 mg/kgSG 12 mg/kgSG 18 mg/kgTotal
Female4628161334
Male3512132161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SG 8mg/kgSG 10 mg/kgSG 12 mg/kgSG 18 mg/kgTotal
Race — White6732963405
Race — Black6192027
Race — Asian4131018
Race — Other4410045
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SG 8mg/kgSG 10 mg/kgSG 12 mg/kgSG 18 mg/kgTotal
Ethnicity — Hispanic or Latino4160020
Ethnicity — Not Hispanic or Latino7738693475
08

Study locations

12 sites
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 080045, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Helen F. Graham Cancer Center
    Newark, Delaware 19713, United States
  • MD Anderson Cancer Center Orlando (UF Health Cancer Center)
    Orlando, Florida 32806, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • IU Health Goshen Cancer Center
    Goshen, Indiana 46526, United States
  • Massachusettes General Hospital
    Boston, Massachusetts 02114, United States
  • Weill Cornell/New York Presbyterian Hospital
    New York, New York 10021, United States
  • Columbia University Herbert Irving Cancer Center
    New York, New York 10032, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37212, United States
  • Texas Oncology Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Virginia Mason Cancer Center
    Seattle, Washington 98111, United States
09

References and documents

Publications

  • Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020 Dec;31(12):1709-1718. doi: 10.1016/j.annonc.2020.09.004. Epub 2020 Sep 15. PubMed 32946924 ↗
  • Santin AD, Komiya T, Goldenberg DM, et al. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase 1/2 study. J Clin Oncol. 2020; 38 (suppl; abstr 6081)
  • Bardia A, Mayer IA, Kalinsky K. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943. No abstract available. PubMed 31189049 ↗
  • Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PubMed 30786188 ↗
  • Tagawa ST, Faltas M, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. J Clin Oncol. 2019;39(suppl 7S):abstr 354.
  • Bardia A, Diamond JR, Vahdat LT, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J Clin Oncol. 2018;36(15 suppl):1004.
  • Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5. PubMed 28679770 ↗
  • Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30. PubMed 28558150 ↗
  • Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26. PubMed 28548889 ↗
  • Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14. PubMed 28291390 ↗
  • Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23. PubMed 26106073 ↗
  • Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5. PubMed 25944802 ↗
  • Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):279-285. doi: 10.1097/COC.0000000000000919. Epub 2022 May 12. PubMed 35728046 ↗
  • Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 Jun;32(6):746-756. doi: 10.1016/j.annonc.2021.03.005. Epub 2021 Mar 16. PubMed 33741442 ↗
  • Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19. PubMed 26541586 ↗
  • Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8. PubMed 25915780 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Mar 2019, 74 months.

Results were first posted in Apr 2021, 2 years 1 month after primary completion.

Of 74 phase 1/2 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 92. This study's 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2012
First posted
Jun 29, 2012
StartActual
Dec 17, 2012
Primary completionActual
Mar 1, 2019
CompletionActual
Aug 13, 2020
Results first posted
Apr 6, 2021
Last update
Aug 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01631552
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 29, 2012
Start date
Dec 17, 2012
Primary completion
Mar 1, 2019
Completion
Aug 13, 2020
Results posted
Apr 6, 2021
Last update
Aug 12, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion